Antioxidant supplementation for lung disease in cystic fibrosis

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 8, 2014, Pages

  Ciofu, Oana ^a   Lykkesfeldt, Jens ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; FATTY ACID; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HYDROGEN PEROXIDE; INTERLEUKIN 6; ISOPROSTANE DERIVATIVE; SELENIUM; SUPEROXIDE DISMUTASE; THIOBARBITURIC ACID REACTIVE SUBSTANCE; TROLOX C; TUMOR NECROSIS FACTOR; TRACE ELEMENT; VITAMIN;

ADVERSE EVENT; ANALYTICAL PARAMETERS; CYSTIC FIBROSIS; DISEASE EXACERBATION; ENZYME ACTIVITY; FATTY ACID BLOOD LEVEL; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPERINFLATION; INFLAMMATION; LIPID PEROXIDATION; LUNG DISEASE; LUNG FUNCTION; LUNG FUNCTION TEST; NUTRITIONAL STATUS; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PLASMA ANTIOXIDANT STATUS; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; QUALITY OF WELL BEING SCALE; REVIEW; SPUTUM ANALYSIS; SUPPLEMENTATION; SYSTEMATIC REVIEW; THERAPY EFFECT; ADULT; CHILD; INHALATIONAL DRUG ADMINISTRATION; META ANALYSIS; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADULT; ANTIOXIDANTS; ASCORBIC ACID; CHILD; CYSTIC FIBROSIS; HUMANS; MICRONUTRIENTS; OXIDATIVE STRESS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELENIUM; VITAMIN E; VITAMINS;

EID: 84907168741     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD007020.pub3     Document Type: Review

References (117)

1. Bishop C, Hudson V, Hilton S, Saxey C, Dastrup T, Redding M, et al.Glutathione augmentation in cystic fibrosis [abstract]. Pediatric Pulmonology 2003;Suppl 25:267-8. [CFGD Register: GN100b; CRS-ID: 5500100000002387]
2. Bishop C, Hudson VM, Hilton SC, Wilde C. A pilot study of the effect of inhaled buffered reduced glutathione on the clinical status of patients with cystic fibrosis. Chest 2005;127(1):308-17. [CFGD Register: GN100d; CRS-ID: 5500100000002682]
3. Bishop CT, Hudson V, Hilton S. Effect of inhaled buffered reduced glutathione (GSH) on the clinical status of cystic fibrosis patients [abstract]. Journal of Cystic Fibrosis 2004;3(Suppl 1):S30. [CFGD Register: GN100c; CRS-ID: 5500100000002582]
4. Bishop CT, Hudson VM, Hilton S, Andrus M, Dastrup BT, Redding M, et al.Effect of inhaled buffered reduced glutathione (GSH) on the clinical status of cystic fibrosis patients [abstract]. American Journal of Respiratory and Critical Care Medicine 2003;167:D041 Poster. [CFGD Register: GN100a; CRS-ID: 5500100000002351]
5. Griese M, Hector A, Kappler M, Ballmann M, Junge S, Rietschel E, et al.Inhaled glutathione in cystic fibrosis [abstract]. Journal of Cystic Fibrosis 2012;11 Suppl 1:S11, Abstract no: WS5.1. [CFGD Register: IB98a; CRS-ID: 5500100000010604]
6. Griese M, Kappler M, Eismann C, Ballmann M, Junge S, Rietschel E, et al.Inhalation treatment with glutathione in patients with cystic fibrosis: a randomized clinical trial. American Journal of Respiratory and Critical Care Medicine 2013;188(1):83-9. [CFGD Register: IB98b; CRS-ID: 5500100000011125; DOI: 10.1164/rccm.201303-0427OC]
7. Harries JT, Muller DP. Absorption of different doses of fat soluble and water miscible preparations of vitamin E in children with cystic fibrosis. Archives of Disease in Childhood 1971;46(247):341-4. [MEDLINE: PMID: 5090667; REFWORKS: ID: 778]
8. Harries JT, Muller DP. Absorption of water miscible and fat soluble preparations of vitamin E in cystic fibrosis [abstract]. Proceedings of the 5th International Cystic Fibrosis Conference; 1969 Sept.22-26; Cambridge, England. 1969:298-307. [CFGD Register: GN49; REFWORKS: ID: 349]
9. Homnick DN, Spillers CR, Cox SR, Cox JH, Yelton LA, /DeLoof MJ, Oliver LK, Ringer TV. Single- and multiple-dose-response relationships of beta-carotene in cystic fibrosis. Journal of Pediatrics 1995;127(3):491-4. [MEDLINE: 95387204; REFWORKS: ID 354]
10. Keljo DJ, Giroir B, Jialal I. Circulating tumor necrosis factor alpha and interleukin-6 levels in cystic fibrosis, effect of vitamin E therapy [abstract]. Pediatric Pulmonology 2000;30(Suppl 20):326. [CFGD Register: GN87; MEDLINE: 95387204; REFWORKS: ID: 355]
11. Levin S. Letter: Muscular performance and vitamin E in cystic fibrosis. Archives of Disease in Childhood 1974;49(3):247. [CFGD Register: GN73a; MEDLINE: PMID: 4596666; REFWORKS: ID: 832]
12. Levin S, Gordon MH, Nitowsky HM, Goldman C, di Sant'Agnese P, Gordon HH. Studies of tocopherol deficiency in infants and children: VI. Evaluation of muscle strength and effect of tocopherol administration in children with cystic fibrosis. Pediatrics 1961;27:578-88. [CFGD Register: GN73b; MEDLINE: 74154485; REFWORKS: ID: 357]
13. Portal B, Richard MJ, Coudray C, Arnaud J, Favier A. Effect of double-blind cross-over selenium supplementation on lipid peroxidation markers in cystic fibrosis patients. Clinica Chimica Acta (International Journal of Clinical Chemistry) 1995;34(1-2):137-46. [CFGD Register: GN47]
14. Portal B, Richard MJ, Ducros V, Aguilaniu B, Brunel F, Faure H, et al.Effect of double-blind crossover selenium supplementation on biological indices of selenium status in cystic fibrosis patients. Clinical Chemistry 1993;39(6):1023-8. [REFWORKS: ID: 361]
15. Engl B, Rust P, Eichler I, Renner S, Elmadfa I. Bioavailability of therapeutic Beta-Carotine (BC) in patients with cystic fibrosis (CF) and effects on anthropometrical parameters over 6 months [abstract]. Monatsschrift fur Kinderheilkunde 1997;145:S 134. [CFGD Register: GN69g; REFWORKS: ID: 353]
16. Renner S, Rath R, Rust P, Lehr S, Frischer T, Elmadfa I, Eichler I. Effects of beta-carotene supplementation for six months on clinical and laboratory parameters in patients with cystic fibrosis. Thorax 2001;56(1):48-52. [CFGD Register: GN69f; REFWORKS: ID: 362]
17. Renner S, Wojnarowski C, Koller DY, Rust P, Elmadfa I, Eichler I. Patients with cystic fibrosis (CF) benefit from ß-Carotene supplementation for 6 months [abstract]. Pediatric Pulmonology 1997;24(Suppl 15):314. [CFGD Register: GN69a; REFWORKS: ID: 350]
18. Renner S, Wojnarowski C, Koller DY, Rust P, Elmadfa I, Eichler I. Patients with cystic fibrosis (CF) benefit from ß-Carotene supplementation for 6 months [abstract]. Proceedings of: 22nd European Cystic Fibrosis Conference; 1998 June 13-19; Berlin, Germany. 1998:97. [CFGD Register: GN69b; REFWORKS: ID: 351]
19. Rust P, Eichler I, Elmadfa I. Influence of an oral beta-carotine-supplementation on the antioxidant status of patients with cystic fibrosis [abstract]. Atemwegs und Lungenkrankheiten 1997;23:51. [CFGD Register: GN69d; REFWORKS: ID: 363]
20. Rust P, Eichler I, Renner S, Elmadfa I. Effects of long-term oral beta-carotene supplementation on lipid peroxidation in patients with cystic fibrosis. International Journal for Vitamin and Nutrition Research 1998;68(2):83-7. [CFGD Register: GN69c; REFWORKS: ID: 364]
21. Rust P, Eichler I, Renner S, Elmadfa I. Long-term oral beta-carotene supplementation in patients with cystic fibrosis - effects on antioxidative status and pulmonary function. Annals of Nutrition & Metabolism 2000;44(1):30-7. [CFGD Register: GN69e; REFWORKS: ID: 365]
22. Visca A, Hilton SC, Hudson VM, Bishop CT. Oral reduced L-glutathione improves weight and calprotectin in pediatric cystic fibrosis patients [abstract]. Journal of Cystic Fibrosis 2013;12 Suppl 1:S64, Abstract no: 62. [CFGD Register: GN232; CRS-ID: 5500100000011567]
23. Wood LG, Fitzgerald DA, Lee AK, Garg ML. Improved antioxidant and fatty acid status of patients with cystic fibrosis after antioxidant supplementation is linked to improved lung function. American Journal of Clinical Nutrition 2003;77(1):150-9. [CFGD Register: GN98; MEDLINE: 2003108743; REFWORKS: ID: 975]
24. Abdulhamid I, Beck FWJ, Millard S, Chen X, Prasad A. Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis. Pediatric Pulmonology 2008;43(3):281-7. [CFGD Register: GN111b]
25. Abdulhamid I, Millard S, Beck F, Chen X, Van Wagnen C, Prasad A. Effect of zinc supplementation on respiratory tract infections in children with cystic fibrosis [abstract]. Pediatric Pulmonology 2005;40 Suppl 28:348. [CFGD Register: GN111a; CRS-ID: 5500100000003010]
26. Anonymous. Vitamin E. The Medical Letter on Drugs and Therapeutics 1975;17(17):69-70. [MEDLINE: PMID: 1152820; REFWORKS: ID: 677]
27. Beddoes V, Laing S, Goodchild MC, Dodge JA. Dietary management of cystic fibrosis. The Practitioner 1981;225(1354):557-60. [MEDLINE: PMID: 7279843; REFWORKS: ID: 697]
28. Best K, McCoy K, Gemma S, Disilvestro RA. Copper enzyme activities in cystic fibrosis before and after copper supplementation plus or minus zinc. Metabolism: Clinical and Experimental 2004;53(1):37-41. [CFGD Register: GN105; CRS-ID: 5500100000002455]
29. Bines JE, Truby HD, Armstrong DS, Carzino R, Grimwood K. Vitamin A and E deficiency and lung disease in infants with cystic fibrosis. Journal of Paediatrics & Child Health 2005;41(12):663-8. [MEDLINE: 2009095173; REFWORKS: ID: 703]
30. Casale A, Tosco A, Buonpensiero P, Di Pasqua A, De Santis S, De Gregorio F, et al.Inhaled GSH tolerability in patients with cystic fibrosis (CF). Journal of Cystic Fibrosis 2012;11 Suppl 1:S69, Abstract no: 51. [CFGD Register: IB97; CRS-ID: 5500100000010603]
31. Cobanoglu N, Ozcelik U, Gocmen A, Kiper N, Dogru D. Antioxidant effect of beta-carotene in cystic fibrosis and bronchiectasis: clinical and laboratory parameters of a pilot study. Acta Paediatrica 2002;91(7):793-8. [REFWORKS: ID: 348]
32. Congden PJ, Bruce G, Rothburn MM, Clarke PC, Littlewood JM, Kelleher J, et al.Vitamin status in treated patients with cystic fibrosis. Archives of Disease in Childhood 1981;56(9):708-14. [MEDLINE: PMID: 7294874; REFWORKS: ID: 727]
33. Ekvall S, Mitchell A. The effect of supplemental vitamin E on vitamin A serum levels in cystic fibrosis. International journal for vitamin and nutrition research.Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition 1978;48(4):324-32. [MEDLINE: PMID: 738846; REFWORKS: ID: 746]
34. Farrell PM, Bieri JG, Fratantoni JF, Wood RE, di Sant'Agnese PA. The occurrence and effects of human vitamin E deficiency. A study in patients with cystic fibrosis. Journal of Clinical Investigation 1977;60(1):233-41. [MEDLINE: PMID: 874086; REFWORKS: ID: 751]
35. Goodchild MC. Practical management of nutrition and gastrointestinal tract in cystic fibrosis. Journal of the Royal Society of Medicine 1986;79(Suppl 12):32-5. [MEDLINE: PMID: 3723545; REFWORKS: ID: 764]
36. Homnic DN, Spillers CR, Cox SR, Cox JH, Yelton LA, DeLoof MJ, et al.Single-and multiple-dose response relationship of beta-carotene in cystic fibrosis. The Journal of Pediatrics 1995;127(3):491-4.
37. Hoogenraad TU. Managing adults with cystic fibrosis. BMJ (Clinical Research Ed) 1989;298(6680):1098. [MEDLINE: PMID: 2497906; REFWORKS: ID: 786]
38. Hubbard VS, Barbero G, Chase HP. Selenium and cystic fibrosis. Journal of Pediatrics 1980;96(3 Pt 1):421-2. [MEDLINE: PMID: 6767009; REFWORKS: ID: 792]
39. Jacquemin E, Hermeziu B, Kibleur Y, Friteau I, Mathieu D, Le Coz F, et al.Bioavailability of oral vitamin E formulations in adult volunteers and children with chronic cholestasis or cystic fibrosis. Journal of Clinical Pharmacy and Therapeutics 2009;34(5):515-22. [CFGD Register: GN216]
40. Kauf E, Janitzky E, Vogt L, Winnefeld K, Dawczynski H, Forberger M, et al.The value of selenotherapy in patients with mucoviscidosis. Medizinische Klinik (Munich, Germany: 1983) 1995;90(Suppl 1):41-5. [MEDLINE: PMID: 7715584; REFWORKS: ID: 811]
41. Kawchak DA, Sowell AL, Hofley PM, Zemel BS, Scanlin TF, Stallings VA. Research and professional briefs. Longitudinal analysis shows serum carotenoid concentrations are low in children with cystic fibrosis. Journal of the American Dietetic Association 1999;99(12):1569-72. [MEDLINE: 2000010146; REFWORKS: ID: 812]
42. Kelleher J, Miller MG, Littlewood JM, McDonald AM, Losowsky. The clinical effect of corrections of vitamin E depletion in cystic fibrosis. International Journal for Vitamin and Nutrition Research (Internationale Zeitschrift für Vitamin und Ernährungsforschung. Journal International de Vitaminologie et de Nutrition) 1987; Vol. 57, issue 3:253-9. [MEDLINE: 8506470; REFWORKS: ID: 813]
43. Knopfle G, Rotthauwe HW, Odenthal A. Serum concentrations of vitamin A, carotene, retinol-binding protein and prealbumin in patients with cystic fibrosis (author's transl). Zeitschrift fur Kinderheilkunde 1975;119(4):279-91. [MEDLINE: PMID: 1136541; REFWORKS: ID: 819]
44. Lancellotti L, D'Orazio C, Mastella G, Mazzi G, Lippi U. Deficiency of vitamins E and A in cystic fibrosis is independent of pancreatic function and current enzyme and vitamin supplementation. European Journal of Pediatrics 1996;155(4):281-5. [MEDLINE: PMID: 8777920; REFWORKS: ID: 825]
45. Lepage G, Champagne J, Ronco N, Lamarre A, Osberg I, Sokol RJ, et al.Supplementation with carotenoids corrects increased lipid peroxidation in children with cystic fibrosis [corrected] [published erratum appears in American Journal of Clinical Nutrition 1997 Feb; 65(2): 578]. American Journal of Clinical Nutrition 1996;64(1):87-93. [MEDLINE: 1996023517; REFWORKS: ID: 829]
46. Madarasi A, Lugassi A, Greiner E, Holics K, Biro L, Mozsary E. Antioxidant status in patients with cystic fibrosis. Annals of Nutrition & Metabolism 2000;44(5-6):207-11. [MEDLINE: PMID: 11146325; anm44207 [pii]; REFWORKS: ID: 844]
47. Mischler EH, Marcus MS, Sondel SA, Laxova A, Carey P, Langhough R, et al.Nutritional assessment of infants with cystic fibrosis diagnosed through screening. Pediatric Pulmonology. Supplement 1991;7:56-63. [MEDLINE: PMID: 1782132; REFWORKS: ID: 850]
48. Munck A, Ginies JL, Huet F, Wizla N, Gerardin M, Darviot E, et al.A new water-soluble oral vitamin E formulation in cystic fibrosis (CF) children [abstract]. Journal of Cystic Fibrosis 2010; Vol. 9 Supplement 1:S91, Abstract no: 352. [CFGD Register: GN219]
49. Nasr SZ, O'Leary MH, Hillermeier C. Correction of vitamin E deficiency with fat-soluble versus water-miscible preparations of vitamin E in patients with cystic fibrosis. Journal of Pediatrics 1993;122(5 (Pt 1)):810-2. [CFGD Register: GN42; REFWORKS: ID: 359]
50. Oermann CM. Anti-inflammatory approaches to the treatment of cystic fibrosis lung disease: past, present and future. Current Opinion in Investigational Drugs (London, England: 2000) 2001;2(7):900-6. [MEDLINE: PMID: 11757788; REFWORKS: ID: 861]
51. Oudshoorn JH, Klijn PH, Hofman Z, Voorbij HA, van der Ent CK, Berger R, et al.Dietary supplementation with multiple micronutrients: no beneficial effects in pediatric cystic fibrosis patients. Journal of Cystic Fibrosis 2007;6(1):35-40. [CFGD Register: GN113; MEDLINE: PMID: 16784903; S1569-1993(06)00070-1 [pii]; REFWORKS: ID: 370]
52. Papas K, Kalbfleisch J, Mohon R. Bioavailability of a novel, water-soluble vitamin E formulation in malabsorbing patients. Digestive Diseases and Sciences 2007;52(2):347-52. [CFGD Register: GN114; MEDLINE: 96204950; REFWORKS: ID: 369]
53. Peters SA, Kelly FJ. Vitamin E supplementation in cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 1996;22(4):341-5. [MEDLINE: PMID: 8732895; REFWORKS: ID: 867]
54. Portal BC, Richard M, Faure HS, Hadjian AJ, Favier AE. Altered antioxidant status and increased lipid peroxidation in children with cystic fibrosis. American Journal of Clinical Nutrition 1995;61(4):843-7.
55. Powell M, Kuitert L. Effect of vitamin K supplementation over one year on bone health in adolescents and adults with cystic fibrosis [abstract]. Pediatric Pulmonology 2010;45(S33):421, Abstract no: 421. [CFGD Register: CO47]
56. Rawal BD, McKay G, Blackhall MI. Inhibition of Pseudomonas aeruginosa by ascorbic acid acting singly and in combination with antimicrobials: in-vitro and in-vivo studies. Medical Journal of Australia 1974;1(6):169-74. [MEDLINE: PMID: 4206887; REFWORKS: ID: 880]
57. Rettammel AL, Marcus MS, Farrell PM, Sondel SA, Koscik RE, Mischler EH. Oral supplementation with a high-fat, high-energy product improves nutritional status and alters serum lipids in patients with cystic fibrosis. Journal of the American Dietetic Association 1995;95(4):454-9. [MEDLINE: PMID: 7699188; S0002-8223(95)00121-2 [pii]; REFWORKS: ID: 884]
58. Richard MJ, Aguilaniu B, Arnaud J, Gout JP, Favier A. Selenium and oxidant injury in patients with cystic fibrosis. Advances in Experimental Medicine and Biology 1990;264:175-8. [MEDLINE: PMID: 2244492; REFWORKS: ID: 886]
59. Rudnik J, Zebrak J, Werys R, Iwanowska C. Results in treatment of children with mucoviscidosis in a sanatorium. Zeitschrift fur Erkrankungen der Atmungsorgane mit Folia Bronchologica 1973;139(2):117-20. [MEDLINE: PMID: 4496390; REFWORKS: ID: 897]
60. Sokol RJ, Butler-Simon N, Heubi JE, Iannaccone ST, McClung HJ, Accurso F, et al.Vitamin E deficiency neuropathy in children with fat malabsorption. Studies in cystic fibrosis and chronic cholestasis. Annals of the New York Academy of Sciences 1989;570:156-69. [MEDLINE: PMID: 2629595; REFWORKS: ID: 919]
61. Sung JH, Park SH, Mastri AR, Warwick WJ. Axonal dystrophy in the gracile nucleus in congenital biliary atresia and cystic fibrosis (mucoviscidosis): beneficial effect of vitamin E therapy. Journal of Neuropathology and Experimental Neurology 1980;39(5):584-97. [MEDLINE: PMID: 7218000; REFWORKS: ID: 933]
62. Uden S, Bilton D, Guyan PM, Kay PM, Braganza JM. Rationale for antioxidant therapy in pancreatitis and cystic fibrosis. Advances in Experimental Medicine and Biology 1990;264:555-72. [MEDLINE: PMID: 2244539; REFWORKS: ID: 943]
63. Underwood BA, Denning CR, Navab M. Polyunsaturated fatty acids and tocopherol levels in patients with cystic fibrosis. Annals of the New York Academy of Sciences 1972;203:237-47. [MEDLINE: PMID: 4512105; REFWORKS: ID: 945]
64. Underwood BA, Denning CR. Blood and liver concentrations of vitamins A and E in children with cystic fibrosis of the pancreas. Pediatric Research 1972;6(1):26-31. [MEDLINE: PMID: 5046968; REFWORKS: ID: 944]
65. van der Vliet A, Eiserich JP, Marelich GP, Halliwell B, Cross CE. Oxidative stress in cystic fibrosis: does it occur and does it matter?. Advances in Pharmacology (San Diego, Calif.) 1997;38:491-513. [MEDLINE: PMID: 8895821; REFWORKS: ID: 948]
66. Winklhofer-Roob BM, Ziouzenkova O, Puhl H, Ellemunter H, Greiner P, Muller G, et al.Impaired resistance to oxidation of low density lipoprotein in cystic fibrosis: improvement during vitamin E supplementation. Free Radical Biology & Medicine 1995;19(6):725-33. [MEDLINE: PMID: 8582644; 0891584995000634 [pii]; REFWORKS: ID: 972]
67. Winklhofer-Roob BM. Beta-carotene supplementation in cystic fibrosis. Journal of Pediatrics 1996;129(1):181-2. [MEDLINE: PMID: 8757591; S0022-3476(96)70228-7 [pii]; REFWORKS: ID: 962]
68. Winklhofer-Roob BM, Shmerling DH, Schimek MG. Response of vitamin E deficient patients with cystic fibrosis (CF) to oral RRR-alpha-tocopherol or all-rac-alpha-tocopheryl acetate [abstract]. Clinical Nutrition 1992;11(Suppl):67. [REFWORKS: ID: 367]
69. Winklhofer-Roob BM, van't Hof MA, Shmerling DH. Long-term oral vitamin E supplementation in cystic fibrosis patients: RRR-alpha-tocopherol compared with all-rac-alpha-tocopheryl acetate preparations. American Journal of Clinical Nutrition 1996;63(5):722-8. [MEDLINE: 96204950; REFWORKS: ID: 368]
70. Winklhofer-Roob BM, Puhl H, Khoschsorur G, van't Hof MA, Esterbauer H, Shmerling DH. Enhanced resistance to oxidation of low density lipoproteins and decreased lipid peroxide formation during beta-carotene supplementation in cystic fibrosis. Free Radical Biology & Medicine 1995;18(5):849-59. [MEDLINE: PMID: 7797092; 089158499400203V [pii]; REFWORKS: ID: 964]
71. Winklhofer-Roob BM, Schlegel-Haueter SE, Khoschsorur G, van't Hof MA, Suter S, Shmerling DH. Neutrophil elastase/alpha 1-proteinase inhibitor complex levels decrease in plasma of cystic fibrosis patients during long-term oral beta-carotene supplementation. Pediatric Research 1996;40(1):130-4. [MEDLINE: PMID: 8798258; REFWORKS: ID: 966]
72. Winklhofer-Roob BM, van't Hof MA, Shmerling DH. Response to oral beta-carotene supplementation in patients with cystic fibrosis: a 16-month follow-up study. Acta Paediatrica (Oslo, Norway: 1992) 1995;84(10):1132-6. [MEDLINE: PMID: 8563224; REFWORKS: ID: 971]
73. Winklhofer-Roob BM. Vitamin E supplementation in cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 1997;25(1):120-2. [MEDLINE: PMID: 9226544; REFWORKS: ID: 960]
74. Winklhofer-Roob BM. Beta-carotene, malondialdehyde, and cystic fibrosis. American Journal of Clinical Nutrition 1997;65(2):575-7. [MEDLINE: PMID: 9022550; REFWORKS: ID: 961]
75. Winklhofer-Roob BM, Ellemunter H, Fruhwirth M, Schlegel-Haueter SE, Khoschsorur G, van't Hof MA, et al.Plasma vitamin C concentrations in patients with cystic fibrosis: evidence of associations with lung inflammation. American Journal of Clinical Nutrition 1997;65(6):1858-66. [MEDLINE: PMID: 9174484; REFWORKS: ID: 963]
76. Winklhofer-Roob BM, Rock E, Ribalta J, Shmerling DH, Roob JM. Effects of vitamin E and carotenoid status on oxidative stress in health and disease. Evidence obtained from human intervention studies. Molecular Aspects of Medicine 2003;24(6):391-402. [MEDLINE: PMID: 14585310; S0098299703000359 [pii]; REFWORKS: ID: 965]
77. Wood LG, Fitzgerald DA, Gibson PG, Cooper DM, Garg ML. Increased plasma fatty acid concentrations after respiratory exacerbations are associated with elevated oxidative stress in cystic fibrosis patients. American Journal of Clinical Nutrition 2002;75(4):668-75. [MEDLINE: 2002132621; REFWORKS: ID: 974]
78. Zoirova RR. Use of the mucolytic agent, mucosolvin, in multiple modality treatment of cystic fibrosis in children. Pediatriia 1983;4(4):36-7. [MEDLINE: PMID: 6877915; REFWORKS: ID: 976]
79. Wong LTK, Halstead C, Davidson AGF, Fang PM. Comparison of the efficacy of water-miscible and fat soluble vitamin E in the therapy of vitamin E deficiency in cystic fibrosis patients [abstract]. Pediatric Pulmonology 1988;5(Suppl 2):144. [REFWORKS: ID: 352]
80. Cystic Fibrosis Foundation. A multi-center, Phase IIB, randomized, placebo-controlled, double-blind study of the effects of N-acetylcysteine on redox changes and lung inflammation in cystic fibrosis patients. http://clinicaltrials.gov/show/NCT00809094 (accessed 23 July 2014).
81. Cystic Fibrosis Foundation Therapeutics Incorporated, Yasoo Health. Effects of an antioxidant-enriched multivitamin supplement on inflammation and oxidative stress in cystic fibrosis (AquADEKs-2). http://clinicaltrials.gov/show/NCT01859390 (accessed 23 July 2014).
82. Benabdeslam H, Abidi H, Garcia I, Bellon G, Gilly R, Revol A. Lipid peroxidation and antioxidant defenses in cystic fibrosis patients. Clinical Chemistry and Laboratory Medicine 1999;37(5):511-6.
83. Bonifant CM, Shevill E, Chang AB. Vitamin A supplementation for cystic fibrosis. Cochrane Database of Systematic Reviews 2012, Issue 8. [DOI: 10.1002/14651858.CD006751.pub3]
84. Brown RK, Kelly FJ. Evidence for increased oxidative damage in patients with cystic fibrosis. Pediatric Research. UNITED STATES, 1994; Vol. 36, issue 4:487-93. [MEDLINE: PMID: 7816524; REFWORKS: ID: 711]
85. Brown RK, Wyatt H, Price JF, Kelly FJ. Pulmonary dysfunction in cystic fibrosis is associated with oxidative stress. European Respiratory Journal. Denmark, 1996; Vol. 9, issue 2:334-9. [MEDLINE: 1996063391; REFWORKS: ID: 994]
86. Canadian Cystic Fibrosis Foundation. Report of the Canadian Patient Data Registry. Canadian Patient Data Registry [Toronto, Ontario] 2002.
87. Cystic Fibrosis Foundation. Patient Registry 2005. Annual Data Report [Bethesda, Maryland] 2005.
88. Cystic Fibrosis Foundation. Cystic Fibrosis Foundation Patient Registry 2012 Annual Data Report. Bethesda, Maryland 2013.
89. Deeks J, Higgins J, Altman D. Chapter 9 Analysing data and undertaking meta-analysis. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
90. Dotan Y, Lichtenberg D, Pinchuk I. Lipid peroxidation cannot be used as a universal criterion of oxidative stress. Progress in Lipid Research. Elsevier, 2004; Vol. 43, issue 3:200-27. [REFWORKS: ID: 1357]
91. Elbourne DR, Altman DG, Higgins JP, Curtin F, Worthington HV, Vail A. Meta-analyses involving cross-over trials: methodological issues. International Journal of Epidemiology 2002; Vol. 31, issue 1:140-9. [REFWORKS: ID: 1347]
92. Ferguson JH, Chang AB. Vitamin D supplementation for cystic fibrosis. Cochrane Database of Systematic Reviews 2012, Issue 4. [DOI: 10.1002/14651858.CD007298.pub3]
93. Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327(7414):557-60.
94. Higgins JPT, Altman DG (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
95. Higgins JPT, Deeks JJ, Altman DG on behalf of the CSMG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook of Systematic Reviews of Interventions. Version 5.1 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
96. Homnick, Douglas. [Trial information for Cochrane review [E-mail]]. Message to: Larissa Shamseer Oct 23, 2008 (cited July 29 2009).
97. Huston P, Moher D. Redundancy, disaggregation, and the integrity of medical research. Lancet 1996; Vol. 347, issue 9007:1024-6. [REFWORKS: ID: 1354]
98. Jagannath VA, Fedorowicz Z, Thaker V, Chang AB. Vitamin K supplementation for cystic fibrosis. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD008482.pub3]
99. Kelly FJ. Glutathione: in defence of the lung. Food and Chemical Toxicology 1999;37(9-10):963-6.
100. Light R, Pillemer D. Summing Up: The Science of Reviewing Research. Cambridge: Harvard University Press, 1984.
101. Mayer-Hamblett N, Aitken ML, Accurso FJ, Kronmal RA, Konstan MW, Burns JL, et al.Association between pulmonary function and sputum biomarkers in cystic fibrosis. American journal of respiratory and critical care medicine. Am Thoracic Soc, 2007:200609. [REFWORKS: ID: 1361]
102. Mayne ST. Antioxidant nutrients and chronic disease: use of biomarkers of exposure and oxidative stress status in epidemiologic research. Journal of Nutrition 2003;133(Suppl 3):933S-40S.
103. Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Medicine 2009;6(6):100097.
104. Montuschi P, Ciabattoni G, Paredi P, Pantelidis P, du Bois RM, Kharitonov SA, et al.8-Isoprostane as a biomarker of oxidative stress in interstitial lung diseases. American Journal of Respiratory and Critical Care Medicine 1998;158(5 Pt 1):1524-7.
105. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al.Interpretative strategies for lung function tests. Series ''ATS/ERS Task Force: Standardisation of lung function testing''. Number 5 in this series. European Respiratory Journal 2005;26(5):948-68.
106. Pryor WA, Stahl W, Rock CL. Beta carotene: from biochemistry to clinical trials. Nutrition Reviews 2000;58(2):39-53.
107. Reed MC, Thomas RL, Pavisic J, James SJ, Ulrich CM, Nijhout HF. A mathematical model of glutathione metabolism. Theoretical Biology & Medical Modelling 2008;5:8. [DOI: 10.1186/1742-4682-5-8]
108. Repine JE, Bast A, Lankhorst I, The Oxidative Stress Study Group. Oxidative Stress in Chronic Obstructive Pulmonary Disease. American Journal of Respiratory and Critical Care Medicine 1997;156(2 Pt 1):341-57.
109. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
110. Rock CL, Jacob RA, Bowen PE. Update on the Biological Characteristics of the Antioxidant Micronutrients Vitamin C, Vitamin E, and the Carotenoids. Journal of the Americal Dietetic Association 1996;96(7):693-702.
111. Roum J.H, Buhl, R, McElvaney, N.G, Borok, Z, Crystal, R.G. Systemic deficiency of glutathione in cystic fibrosis. Journal of Applied Physiology 1993;75(6):2419-2424.
112. Schunemann HJ, Muti P, Freudenheim JL, Armstrong D, Browne R, Klocke RA, et al.Oxidative stress and lung function. American Journal of Epidemiology 1997;146(11):939-48.
113. Stick SM, Brennan S, Murray C, Douglas T, von Ungern-Sternberg BS, Garratt LW, et al.Bronchiectasis in infants and preschool children diagnosed with cystic fibrosis after newborn screening. Journal of Pediatrics 2009;155(5):623-8.
114. Tirouvanziam R, Conrad CK, Bottiglieri T, Herzenberg LA, Moss RB, Herzenberg L. High-dose oral N-acetylcysteine, a glutathione prodrug, modulates inflammation in cystic fibrosis. Proceedings of the National Academy of Sciences of the United States of America 2006;103(12):4628-33.
115. Wenninger, K, Aussage P, Wahn, U, Staab, D, German Cystic Fibrosis Questionnaire Study Group. The revised German Cystic Fibrosis Questionnaire: validation of a disease-specific health-related quality of life instrument. Quality of Life Research 2003;12(1):77-85.
116. Winklhofer-Roob BM. Oxygen free radicals and antioxidants in cystic fibrosis: the concept of an oxidant-antioxidant imbalance. Acta Paediatrica 1994;83(395):49-57.
117. Wood LG, Fitzgerald DA, Gibson PG, Cooper DM, Collins CD, Garg ML. Oxidative Stress in Cystic Fibrosis: Dietary and Metabolic Factors. Journal of the American College of Nutrition 2001;20(2):157-65.